Farallon Capital Management’s Parabilis Medicines Inc PBLS Stock Holding History

Farallon Capital Management’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.8M	Buy	+2,368,200	New	+$65.4M	0.3%	37

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Farallon Capital Management's PBLS Position: Q2 2026 in Review

Farallon Capital Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 2,368,200 shares worth $64.8M. The stake represents 0.3% of the portfolio and ranks #37 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Farallon Capital Management held 2,368,200 shares of Parabilis Medicines Inc worth $64.8M as of Q2 2026.
Parabilis Medicines Inc was a new Farallon Capital Management position in Q2 2026.
Parabilis Medicines Inc made up 0.3% of Farallon Capital Management's portfolio in Q2 2026, its #37 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.